Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Remogliflozin etabonate (GSK189075A) is a prodrug of regaliflozin and an inhibitor SGLT2 with Ki values of 1.95, 2.14, 8.57, and 43.1μM for hSGLT2, rSGLT2, rSGLT1, and hSGLT1, respectively.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 37.00 | |
5 mg | In stock | $ 89.00 | |
10 mg | In stock | $ 172.00 | |
25 mg | In stock | $ 347.00 | |
50 mg | In stock | $ 563.00 | |
100 mg | In stock | $ 812.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 97.00 |
Description | Remogliflozin etabonate (GSK189075A) is a prodrug of regaliflozin and an inhibitor SGLT2 with Ki values of 1.95, 2.14, 8.57, and 43.1μM for hSGLT2, rSGLT2, rSGLT1, and hSGLT1, respectively. |
Targets&IC50 | SGLT1 (human):43.1 μM (Ki), SGLT1 (rat):8.57 μM (Ki), SGLT2 (rat):2.14 μM (Ki), SGLT2 (human):1.95 μM (Ki) |
In vivo | Oral administration of Remogliflozin etabonate (10-30 mg/kg) dose-dependently reduces the levels of FPG and GHb. Oral administration of Remogliflozin etabonate (3-30 mg/kg) dose-dependently increases urine volume and urinary glucose excretion[2]. |
Synonyms | GSK189075, GSK 189075, GSK-189075A, GSK189075A, GSK-189075, GSK 189075A |
Molecular Weight | 522.59 |
Formula | C26H38N2O9 |
CAS No. | 442201-24-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 90.0 mg/mL (172.2 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Remogliflozin etabonate 442201-24-3 GPCR/G Protein SGLT GSK189075 GSK 189075 GSK-189075A GSK189075A GSK-189075 GSK 189075A inhibitor inhibit